<DOC>
	<DOCNO>NCT02395133</DOCNO>
	<brief_summary>The primary objective study assess ability different dupilumab dose regimen , administer monotherapy , maintain treatment response achieve 16 week initial treatment dupilumab monotherapy compare placebo .</brief_summary>
	<brief_title>A Study Confirm Efficacy Safety Different Dupilumab Dose Regimens Adults With Atopic Dermatitis ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Key 1 . Must complete treatment phase 1 two 16week initial treatment study ( R668AD1334 R668AD1416 ) . 2 . Must achieve least 1 follow 2 treatment success criterion : IGA = 0 1 ( clear almost clear ) week 16 OR EASI75 ( least 75 % reduction EASI score baseline week 16 ) 3 . Must willing able comply clinic visit studyrelated procedure 4 . Must provide sign informed consent 5 . Must able understand complete studyrelated questionnaire Key 1 . Receipt rescue medication AD initial treatment study 2 . Any condition require permanent discontinuation study treatment either initial treatment study 3 . Planned anticipated major surgical procedure patient 's participation study 4 . Pregnant breastfeed woman , woman plan become pregnant breastfeed study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Eczema</keyword>
</DOC>